Read-Gene S.A. is a Poland-based biotechnology company that specializes in the development and commercialization of genetic testing services. Its primary focus is on the identification and analysis of genetic predispositions to various forms of cancer, offering comprehensive diagnostic solutions to promote early detection and intervention. The company's core services include BRCA1 and BRCA2 mutation tests, crucial for assessing breast and ovarian cancer risk. With a strong foundation in scientific research, Read-Gene S.A. partners with leading medical institutions and universities to advance genetic profiling technologies. It plays a pivotal role in the medical and research sectors, influencing patient care approaches by enabling personalized medicine strategies. In the financial market, Read-Gene S.A. acts as an important player within the healthcare and biotechnology segments, reflecting growing interest in genetic information's role in preventative health care.